Skip to main content
OpenTrials
Completed

NCT Number: NCT02680366

Treatment of Severe Asherman Syndrome by Collagen Scaffold Loaded With Autologous Bone Marrow Mononuclear Cells

This study evaluates the addition of collagen scaffold loaded with autologous bone marrow mononuclear cells(ABMNC) to Foley catheter balloon after hysteroscopic adhesiolysis in the treatment of severe asherman syndrome. Half of participants will receive collagen/ABMNC scaffold after hysteroscopic adhesiolysis, while the other half will receive Foley catheter balloon.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Nanjing Drum Tower Hospital

Nanjing, Jiangsu, 210008, China

About this study

Severe asherman syndrome will lead to infertility, and the most common method to treat asherman syndrome is operating to dissect adhesions. In order to prevent the postoperative re-adhesion, many physical isolation measures have been tried. However, they don't improve the microenvironment of endometrial regeneration. It's reported that bone marrow mononuclear cells have good effects on the functional recovery of injured uterus. This study will determine whether collagen scaffolds loaded with autologous bone marrow mononuclear cells will be more effective than Foley balloon catheters at treating infertile women with severe intrauterine adhesions who have taken hysteroscopic adhesiolysis. In addition, the study will be carried out in 2 centers, one is the Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, the other is Changzhou Maternal and Child Health Care Hospital that is in Jiangsu Province.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Having a clear desire to fertility;
  • Infertility that is defined as a women fails to become pregnant after having a normal sex life for two years without contraception.
  • Hysteroscopy examination confirmed intrauterine adhesions(patients who has at least one of the three symptoms which are amenorrhea, hypomenorrhea or infertility, and hysteroscopy or histologic diagnosis of intrauterine adhesions), meeting American Fertility Society diagnostic criteria Ⅱ-III;
  • Normal ovarian function;
  • Regular Menstrual cycles and menstruation is normal before abortion or curettage;
  • BMI< 30 kg/m2;
  • Sign a consent form;
  • Follow the test plan and follow-up process.

Exclusion criteria

  • Hereditary diseases;
  • Simple thin endometrium with no uterine cavity adhesion;
  • Simple Uterine scar formation with no uterine cavity adhesion after hysteroscopic adhesiolysis;
  • Contraindications to bone marrow collection or assisted reproductive technology;
  • History of malignant tumor;
  • Other diseases associated with the uterus: uterine fibroids, severe adenomyosis, severe malformations of the uterus;
  • Abnormal blood coagulation, liver and kidney dysfunction, or other diseases which the researchers think may affect the study(such as: uncontrolled hypertension, diabetes, sexually transmitted diseases);
  • With a positive urine pregnancy test;
  • Participating in other clinical studies at the same time;
  • Hysteroscopic adhesiolysis more than 3 times in the past.

Treatment and study plan

collagen/ABMNC scaffold

Device

The patients will receive a bone marrow puncture to collect bone marrow cells which are used to isolation of ABMNCs. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. Then, the collagen/ABMNCs scaffold was covered on a Foley catheter balloon and placed into the uterine cavity. The catheter balloon was kept for 24 hours and then removed. Oral antibiotics were given to prevent infection in the second and third days after operation. 72 hours after the surgery, a vaginal speculum examinations will be done in order to make patients unknown about their arms. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.

Foley catheter balloon

Device

The patients will receive a sham bone marrow puncture which just has a local anesthesia and collects no bone marrow cells to isolation. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. And then, a Foley catheter balloon will be placed into the uterine cavity and kept for 72 hours before it is removed. Oral antibiotics were given to prevent infection in the second and third days after operation. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.

Primary outcomes

  1. Ongoing pregnancy rate

    Time frame: up to 24 months

    A successful clinical pregnancy means that at the 12th week of pregnancy, ultrasound reveals that the fetus had a heart activity and the size of the fetus is in consistent with the gestational week.

Secondary outcomes

  1. Menstrual volumes and menstrual improvement:

    Time frame: at 3 and 6 months post-operation

    PBAC scores in the third and sixth menstrual cycles after the initial adhesiolysis and PBAC scores increase compared to pre-operation

  2. Maximal endometrial thickness

    Time frame: at 3 and 6 months post-operation

    Measure the endometrial thickness during ovulation by ultrasound by the same trained medical sonographers at 3 and 6 months after surgery, comparing with pre-operation.

  3. Re-adhesion rate at the second-look hysteroscopy

    Time frame: at 3 months post-operation

  4. AFS score at the second-look hysteroscopy and AFS score decrease compared to pre-operation

    Time frame: at 3 months post-operation

  5. Miscarriage rate

    Time frame: up to 24 months

  6. preterm birth rate

    Time frame: up to 24 months

  7. ectopic pregnancy rate

    Time frame: up to 24 months

  8. live birth rate

    Time frame: up to 24 months

Sponsors and collaborators

Lead sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Other

Collaborators

  • Changzhou Maternal and Child Care Hospital

Registry information

Official study title

A Multi-center, Randomized, Single-blind, Controlled Clinical Trial of Treatment of Severe Asherman Syndrome by Collagen Scaffold Loaded With Autologous Bone Marrow Mononuclear Cells

Important dates

Study start
2016
Primary completion
2022
Study completion
2022
First posted
Feb 11, 2016
Registry last updated
Nov 30, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.